Vanguard
http://www.vanguard.com/Vanguard, an investment management company, offers mutual funds and other financial products and services to institutional and individual investors worldwide.
View Older Stories View More Recent Stories
-
Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange
-
NYC-based Quantbase raises $500k pre-seed to make smart high-risk investing effortless
-
Vanguard Announces Cash Distributions for the Vanguard ETFs (VFV and VSP)
-
How Kronos, the White House, and the DOE Can Build a Fusion Energy Commercialization Center
-
Health Technology Start-up MedMe Health Secures $2.7 Million Seed Investment led by M12 – Microsoft's Venture Fund
-
Advanced Micro Devices, Inc. (AMD) Introduces AMD Software: Adrenalin Edition 2022
-
Introducing AMD Software: Adrenalin Edition 2022 Release and AMD FidelityFX Super Resolution 2.0 – Delivering High-Performance and Visually Stunning Gaming Experiences
-
Introducing AMD Software: Adrenalin Edition 2022 Release and AMD FidelityFX Super Resolution 2.0 – Delivering High-Performance and Visually Stunning Gaming Experiences
-
Form 8-K AMERICAN VANGUARD CORP For: Mar 14
-
Vanguard Announces Cash Distributions for the Vanguard ETFs (VUN, VUS and VXC)
-
ACADEMY AWARD-NOMINATED FILMMAKER STANLEY NELSON AND JACQUELINE OLIVE SET TO DIRECT 'THE COLOR OF COLA' DOCUMENTARY CHRONICLING THE JOURNEY OF PEPSI'S ALL-BLACK SALES FORCE IN THE JIM CROW SOUTH
-
Quit Genius Hires Harvard-Trained, Digital Health Executive and Dual-Board Certified Assistant Professor of Medicine as Medical Director
-
Wells Fargo Enhances Fraud Protection and Customer Experience Using FICO Solutions
-
Flippa Launches "Alts" - A New Community for Alternative Asset Investors
-
Adagene Inc. (ADAG) Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
-
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
-
3D Display Market Size, Share, Industry Analysis, Growth Strategies, Demand Forecast, Trends, Sales Revenue and Forecast 2027
-
Form N-CEN Vanguard Montgomery Fund For: Dec 31
-
Form N-CEN VANGUARD BOND INDEX FUND For: Dec 31
-
Form N-CEN VANGUARD TAX-MANAGED For: Dec 31
-
Form N-CEN VANGUARD INDEX FUNDS For: Dec 31
-
Form N-CEN VANGUARD INSTITUTIONAL For: Dec 31
-
Form N-CEN VANGUARD VARIABLE INSURA For: Dec 31
-
Form N-CEN VANGUARD VALLEY FORGE For: Dec 31
-
Impress Communications Supports Project C.U.R.E. in the Fight Against Covid-19
-
Form 24F-2NT VANGUARD VARIABLE INSURA For: Dec 31
-
Form 24F-2NT VANGUARD VALLEY FORGE For: Dec 31
-
Form 24F-2NT VANGUARD TAX-MANAGED For: Dec 31
-
Form 24F-2NT Vanguard Montgomery Fund For: Dec 31
-
Form 24F-2NT VANGUARD INSTITUTIONAL For: Dec 31
-
Form 24F-2NT VANGUARD INDEX FUNDS For: Dec 31
-
Form 24F-2NT VANGUARD BOND INDEX FUND For: Dec 31
-
IBM to Anchor SL Green’s Transformative New Development at One Madison Avenue
-
The Massman Companies Acquires New England Machinery, Inc.
-
Vanguard Announces Cash Distributions for the Vanguard ETFs
-
American Vanguard Declares Quarterly Dividend and Sets 2022 Annual Shareholders’ Meeting
-
Factbox-Stranded assets: How many billions are stuck in Russia?
-
Form 10-K AMERICAN VANGUARD CORP For: Dec 31
-
Dealer eProcess Wins 2022 AWA Awards
-
Form 8-K AMERICAN VANGUARD CORP For: Mar 08
-
The Saver's Dilemma: Where to put your cash now?
-
Defence firms ramp up pitch to exit sustainability wilderness
-
Symbiont Announces Expansion of Executive Leadership Team Naming New Chief Marketing Officer & Chief People Officer
-
Elevating Large Volume Cryptocurrency Services with VirgoCX Wealth
-
American Lithium Corp. (TSX.V: LI) (OTCQB: LIACF) Featured in Virtual Coverage of the 34th Annual Roth Conference
-
Roofstock raises $240M at $1.9B valuation to expand access to real estate investing
-
JD.com Announces Fourth Quarter and Full Year 2021 Results
-
JD.com Announces Fourth Quarter and Full Year 2021 Results
-
MAPTYCS® Named to Guidewire Insurtech Vanguards Program
-
Romark's Vanguard Co-V Clinical Trial Published in Lancet's eClinicalMedicine

